JP2019537619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537619A5 JP2019537619A5 JP2019538088A JP2019538088A JP2019537619A5 JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5 JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 108090001123 antibodies Proteins 0.000 claims 24
- 102000004965 antibodies Human genes 0.000 claims 24
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 14
- 229960002621 pembrolizumab Drugs 0.000 claims 12
- 108010026276 pembrolizumab Proteins 0.000 claims 12
- 210000004369 Blood Anatomy 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 11
- 238000002965 ELISA Methods 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000038129 antigens Human genes 0.000 claims 7
- 108091007172 antigens Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100019764 PDCD1 Human genes 0.000 claims 5
- 108060007796 SPATA2 Proteins 0.000 claims 5
- 229950007843 Bavituximab Drugs 0.000 claims 4
- 108010001114 bavituximab Proteins 0.000 claims 4
- 230000003442 weekly Effects 0.000 claims 4
- 230000001809 detectable Effects 0.000 claims 3
- 102100007475 APOH Human genes 0.000 claims 2
- 101700082784 APOH Proteins 0.000 claims 2
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000001394 metastastic Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 230000036868 Blood Concentration Effects 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000112 colonic Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400589P | 2016-09-27 | 2016-09-27 | |
| US62/400,589 | 2016-09-27 | ||
| US201662406727P | 2016-10-11 | 2016-10-11 | |
| US62/406,727 | 2016-10-11 | ||
| US201762480994P | 2017-04-03 | 2017-04-03 | |
| US62/480,994 | 2017-04-03 | ||
| US201762507580P | 2017-05-17 | 2017-05-17 | |
| US62/507,580 | 2017-05-17 | ||
| PCT/US2017/053370 WO2018064013A1 (en) | 2016-09-27 | 2017-09-26 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537619A JP2019537619A (ja) | 2019-12-26 |
| JP2019537619A5 true JP2019537619A5 (ru) | 2020-11-12 |
Family
ID=66538296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538088A Pending JP2019537619A (ja) | 2016-09-27 | 2017-09-26 | β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3519827A1 (ru) |
| JP (1) | JP2019537619A (ru) |
| KR (1) | KR20190057303A (ru) |
| CN (1) | CN109863402A (ru) |
| AU (1) | AU2017334698A1 (ru) |
| CA (1) | CA3037008A1 (ru) |
| MX (1) | MX2019003569A (ru) |
| WO (1) | WO2018064013A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11571459B2 (en) | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
| CA3106997A1 (en) * | 2018-08-13 | 2020-02-20 | Regeneron Pharmaceuticals, Inc. | Therapeutic protein selection in simulated in vivo conditions |
| AU2021269832B2 (en) * | 2020-05-12 | 2024-09-19 | Astrazeneca Ab | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| CN114716547B (zh) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 |
| WO2024065243A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Macau | Drug for treatment of breast cancer and application thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| PT1520588E (pt) | 1998-07-13 | 2015-03-31 | Univ Texas | Usos de anticorpos para amino fosfolípidos para o tratamento do cancro |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| DK1853631T3 (en) | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| KR101502267B1 (ko) | 2007-11-09 | 2015-03-18 | 페레그린 파마수티컬즈, 인크 | 항-ｖｅｇｆ 항체 조성물 및 방법 |
| CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| DK3279215T3 (da) | 2009-11-24 | 2020-04-27 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| NZ723336A (en) | 2014-02-27 | 2017-04-28 | Univ Texas | Methods and compositions for isolating exosomes |
| SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
-
2017
- 2017-09-26 CA CA3037008A patent/CA3037008A1/en not_active Abandoned
- 2017-09-26 KR KR1020197008828A patent/KR20190057303A/ko not_active Application Discontinuation
- 2017-09-26 MX MX2019003569A patent/MX2019003569A/es unknown
- 2017-09-26 JP JP2019538088A patent/JP2019537619A/ja active Pending
- 2017-09-26 EP EP17791768.9A patent/EP3519827A1/en not_active Withdrawn
- 2017-09-26 CN CN201780058161.8A patent/CN109863402A/zh active Pending
- 2017-09-26 AU AU2017334698A patent/AU2017334698A1/en not_active Abandoned
- 2017-09-26 WO PCT/US2017/053370 patent/WO2018064013A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537619A5 (ru) | ||
| Zhao et al. | Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy | |
| Levy et al. | Targeting autophagy in cancer | |
| Wu et al. | Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| ES2734673T3 (es) | Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas | |
| AU2018288060B2 (en) | IL-1beta binding antibodies for use in treating cancer | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| Li et al. | Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells | |
| JP6381735B2 (ja) | 併用抗がん剤の感受性判定マーカー | |
| Meghnani et al. | The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors | |
| JP2023156343A (ja) | がん幹細胞の低減におけるｗｎｔ５ａペプチド | |
| Park et al. | GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer | |
| JP7369378B2 (ja) | 抗がん剤及びがんを治療するための医薬組成物 | |
| Greening et al. | Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways | |
| Joseph et al. | STING activation counters glioblastoma by vascular alteration and immune surveillance | |
| WO2018235056A1 (en) | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER | |
| Dittrich et al. | A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors | |
| Deneka et al. | Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model | |
| JP2017535548A5 (ru) | ||
| Simeone et al. | A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600 BRAF mutation | |
| US11813305B2 (en) | Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer | |
| CN117425515A (zh) | 用交变电场和曲妥珠单抗的组合进行治疗的组合物和方法 | |
| Loilome et al. | Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma |